Market Insight Cell & Gene

OC-1:CAR T CD1 Immunotherapies For T-ALL

Sonia Macia

Chief Medical Officer

Aromics Therapeutics

15 July, 2026

Watch time: 15 Minutes

Highlights

Takeaways

•Overview of novel CAR T-cell therapies targeting CD1 for treatment-resistant T-ALL
•Discussion of preclinical findings and emerging strategies in CD1-directed immunotherapy development
•How to speed up a clinical development program for CAR-T therapies in a rare indication
•Clinical and regulatory challenges

Sonia Macia, Chief Medical Officer, OneChain Immunotherapeutics

PREMIUM CONTENT

Want that extra level of detail?
Subscribe and get access to full length presentations and write-ups giving you the insights to stay ahead of the curve.

Please note once we have received payment it can take 24 hours for your account to be updated to the premium access.

Upgrade

Full Video Transcript